Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has few
beneficial treatments for patients.
Recently, the involvement of pyruvate dehydrogenase (PDH) in ME/CFS has
been reported. However, it is little
PDH could be a therapeutic target of ME/CFS.
In this paper, Ohba et al.
established ME/CFS model in mice and investigated the involvement of PDH. In an ME/CFS group, PDH activity was
decreased in the mitochondrial fraction of the gastrocnemius muscle. Sodium dichloroacetate (DCA), which is a PDH
activator, recovered fatigue-like behavior in ME/CFS group. These findings indicate that PDH might be an
important therapeutic target for treatment of ME/CFS.